Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Omar Oliveros

Internal Medicine Chicago, IL Medical Doctor

NPI 1538542337 CMS profile 1364435

4417 W Diversey Ave, Chicago, IL 60639

Open in the dashboard

General payments

$10,883

385 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Omar Oliveros of Chicago, IL is reported in the CMS Open Payments database as having received $10,883 across 385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,531 59
2024 General $2,196 66
2023 General $1,467 56
2022 General $1,704 43
2021 General $1,960 87
2020 General $1,193 48
2019 General $831 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Omar Oliveros
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Omar Oliveros were reported at $1,531. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Omar Oliveros Internal Medicine median Middle half National median
2019 $831 $159 $48–$570 $163
2020 $1,193 $119 $33–$402 $114
2021 $1,960 $135 $37–$521 $132
2022 $1,704 $141 $42–$496 $149
2023 $1,467 $149 $45–$519 $160
2024 $2,196 $154 $47–$537 $164
2025 $1,531 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,555 61 payments
  2. Novo Nordisk Inc $1,524 56 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,230 52 payments
  4. Amgen Inc. $1,095 28 payments
  5. AbbVie, Inc. $557 34 payments
  6. Lilly USA, LLC $545 25 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $520 16 payments
  8. Corcept Therapeutics $417 15 payments
  9. GlaxoSmithKline, LLC. $385 14 payments
  10. RedHill Biopharma Inc. $307 27 payments
  11. Other $1,747 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,852 383 payments
  2. Education $31 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,093 33 payments
  2. JARDIANCE $747 32 payments
  3. RYBELSUS $702 36 payments
  4. Repatha $658 18 payments
  5. BREZTRI $640 14 payments
  6. Ozempic $601 37 payments
  7. AIRSUPRA $567 9 payments
  8. Wegovy $503 11 payments
  9. Kerendia $492 15 payments
  10. Korlym $417 15 payments
  11. Other $6,287 277 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 115 drugs

Part D claims

6,485

Median for Internal Medicine: 777

Drug cost

$899,146

Median for Internal Medicine: $73,373

Branded share of claims

21%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 104 $156,746
Farxiga Dapagliflozin Propanediol Brand 99 $122,577
Rybelsus Semaglutide Brand 50 $105,157
Ozempic Semaglutide Brand 34 $57,037
Kerendia Finerenone Brand 34 $53,611
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 30 $47,614
Linzess Linaclotide Brand 37 $44,753
Creon Lipase/Protease/Amylase Brand 11 $42,372
Trulicity Dulaglutide Brand 26 $42,136
Vascepa Icosapent Ethyl Brand 25 $26,418

The 10 drugs with the highest cost, of 115 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $381
$381 104 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $253
$253 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $235
$235 34 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $201
$201 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $169
$169 99 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record